401 research outputs found
Saint Augustine's Critical Judgment of the Pagan Writers
No full textThe following is an attempt to study Saint Augustine’s attitude toward the Greek and Latin pagan writers. An effort has been made to record all of the direct quotations of the pagan authors used by Saint Augustine in the twenty-two books of his Be Civitate Dei. |I have undertaken to emphasize the fact that the number of times an author has been quoted and the manner in which each author has been described somewhat emphasizes Augustine’s judgment of them. |Therefore, with the chart containing the above mentioned information, I have included short commentaries and recordings of those quotations to indicate Augustine’s appraisal of those who were responsible for them.ProQuest Traditional Publishing Optio
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
No full textBACKGROUND: The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain intrinsic resistance to other anti-angiogenic drugs is 'vessel co-option,' ie, the ability of tumors to hijack the existing vasculature in organs such as the lungs or liver, thus limiting the need for sprouting angiogenesis. Vessel co-option has not been evaluated as a potential mechanism for acquired resistance to anti-angiogenic agents. METHODS: To study sorafenib resistance mechanisms, we used an orthotopic human HCC model (n = 4-11 per group), where tumor cells are tagged with a secreted protein biomarker to monitor disease burden and response to therapy. Histopathology, vessel perfusion assessed by contrast-enhanced ultrasound, and miRNA sequencing and quantitative real-time polymerase chain reaction were used to monitor changes in tumor biology. RESULTS: While sorafenib initially inhibited angiogenesis and stabilized tumor growth, no angiogenic 'rebound' effect was observed during development of resistance unless therapy was stopped. Instead, resistant tumors became more locally infiltrative, which facilitated extensive incorporation of liver parenchyma and the co-option of liver-associated vessels. Up to 75% (±10.9%) of total vessels were provided by vessel co-option in resistant tumors relative to 23.3% (±10.3%) in untreated controls. miRNA sequencing implicated pro-invasive signaling and epithelial-to-mesenchymal-like transition during resistance development while functional imaging further supported a shift from angiogenesis to vessel co-option. CONCLUSIONS: This is the first documentation of vessel co-option as a mechanism of acquired resistance to anti-angiogenic therapy and could have important implications including the potential therapeutic benefits of targeting vessel co-option in conjunction with vascular endothelial growth factor receptor signaling
Reclaiming Our Democracy: Challenging Global Poverty and Climate Change through Civic Action
No full textThe Center for Global Education\u27s Global Topics Series Fall 2013 Lecture was delivered by Sam Daley-Harris, global activist, author and microfinance trailblazer. His work on the international Microcredit Summit Campaign has brought global microloans to over 100 million impoverished families, and has helped bring issues of climate change into the national spotlight. A close collaborator of Nobel Prize Laureate Muhammad Yunus and recent TED Talks presenter, Daley-Harris has pioneered a brand of activism that inspires ordinary citizen to effectively engage the political and media establishements in order to make their voices and causes heard -- and heeded
SOX11 promotes invasive growth and ductal carcinoma<i>in situ</i>progression
No full textSupporting information is available online at: https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4939#support-information-section .Copyright © 2017 The Authors. Here, we show that SOX11, an embryonic mammary marker that is normally silent in postnatal breast cells, is expressed in many oestrogen receptor-negative preinvasive ductal carcinoma in situ (DCIS) lesions. Mature
mammary epithelial cells engineered to express SOX11 showed alterations in progenitor cell populations, including an expanded basal-like population with increased aldehyde dehydrogenase (ALDH) activity, and increased mammosphere-forming capacity. DCIS.com cells engineered to express SOX11 showed increased ALDH activity, which is a feature of cancer stem cells. The CD44+/CD24–/ALDH+ cell population was increased in DCIS.com cells that expressed SOX11. Upregulating SOX11 expression in DCIS.com cells led to increased invasive growth both in vitro and when they were injected intraductally in a mouse model of DCIS that recapitulates human disease. Invasive lesions formed sooner and tumour growth was augmented in vivo, suggesting that SOX11 contributes to the progression of DCIS to invasive breast cancer. We identified potential downstream effectors of SOX11 during both microinvasive and invasive tumour growth stages, including several with established links to regulation of progenitor cell function and prenatal developmental growth. Our findings suggest that SOX11 is a potential biomarker for DCIS lesions containing cells harbouring distinct biological features that are likely to progress to invasive breast cancer.Breast Cancer Now;
Wellcome Trust. Grant Number: 090532/Z/09/Z;
CRUK. Grant Number: CRUK/08/046;
Cancer Research UK;
The British Columbia Cancer Agency Branch
The winning ticket : Daley, the Chicago machine, and Illinois politics
No full text"Copublished with the Eagleton Institute of Politics, Rutgers University.
Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.
No full textRefining current prognostic capability is essential for improving the management of melanoma. This study was undertaken to develop a tumor array for the rapid assessment of novel prognostic markers in a series of specimens from melanoma patients with 7- to 10-year follow-up. A melanoma database of 120 patients with archival specimens was created after histopathological review of original specimens. A tissue array was developed allowing 480 biopsy samples from the 120 primary melanoma specimens to be embedded into a single paraffin block. This was sectioned and stained for the adhesion marker melanoma cell adhesion molecule (MCAM); after further review, 76 of the 120 specimens were suitable for further analysis. The slides were assessed by two independent observers without previous knowledge of the clinical outcome for staining positivity and stain intensity. Assessment of association between MCAM and clinicopathological features was carried out using chi-squared analysis, and univariate and Cox multivariate analyses were performed on the data. There was a high correlation between MCAM intensity and both Clark's level and Breslow thickness (Spearman correlation p < 0.001 for both). The data revealed that MACM was a highly specific prognostic marker for survival in univariate analysis (chi2 = 18, p < 0.0001). Subgroup analysis by stratification of the staining intensity revealed a sequentially worsening survival with increasing staining intensity (chi2 = 22.33, p < 0.0001). Multivariate analysis of survival showed MCAM to be an independent prognostic marker more accurate than all other clinicopathological parameters (p < 0.0001), including the Breslow depth. Further analysis within only intermediate-thickness tumors showed MCAM intensity added further refinement to outcome prediction (chi2 = 22.33, p < 0.0001). The tissue array provided a rapid method of analyzing up to 480 specimens within a single paraffin block. This will benefit many areas of plastic surgery research. The identification of adhesion markers revealed a valuable prognostic marker for predicting outcome and a potential target for therapeutic manipulation
Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy
No full textPurpose: Identification of factors that assist prediction of tumor response to radiotherapy may aid in refining treatment strategies and improving outcome. Possible association of molecular marker expression profiles with locoregional control of head and neck squamous cell carcinoma was investigated in a randomized trial of conventional versus continuous hyperfractionated accelerated radiotherapy (CHART). Experimental design: Tumor material was obtained from 402 patients. Immunohistochemistry was used to assess Ki-67, CD31, p53, Bcl-2, and cyclin D1 expression. A hierarchical clustering algorithm with a Bayesian information criterion was used to group tumors with similar marker expression; resulting expression profiles were then compared in terms of their difference in outcome after CHART and conventionally fractionated radiotherapy. Results: Molecular marker profile was an independent prognostic factor for locoregional control. This was confirmed in multivariate analysis, including clinical variables such as tumor and nodal status, primary site, histological grade, age, and gender (P < 0.001 and P = 0.006 for local and nodal relapse, respectively). In particular, Bcl-2-positive tumors responded significantly better than average in both arms of the trial. Tumors negative for p53- and Bcl-2, with high and randomly patterned Ki-67 expression, responded worse than average with no benefit from CHART. Tumors with similarly negative p53 and Bcl-2, but low Ki-67 staining, with an organized pattern, benefit significantly from CHART schedule. Conclusions: This study demonstrates the potential of molecular profiles to predict radiotherapy response of head and neck squamous cell carcinoma and for treatment stratification. Distinct expression profiles correlate with three distinct clinical phenotypes, including good locoregional control, poor locoregional control, and an outcome strongly dependent upon fractionation schedule
An Analysis of and Conductor\u27s Guide to Eleanor Daley\u27s Requiem
No full textThis study provides a thorough analysis of and conductor\u27s guide to Eleanor Daley\u27s Requiem. It includes a theoretical analysis, a textual analysis, an analysis of performance and conducting considerations, a list of compositions by the composer, and a discography. Additionally, it includes score corrections, the composer\u27s biography, a brief history of the Requiem Mass and Christian funeral music, and historical connections to other Requiems, including a chapter dedicated to the Requiem of Herbert Howells.
The study was informed by numerous correspondences and multiple interviews with the composer, as well as singing under her direction. It is the author\u27s hope that this study will encourage and equip future conductors to program this exceptional composition, and encourage greater exploration of other accessible modern works
[McCleary Record on Appeal]
No full textContinues the Submission of Deposition Testimony by Edwin Glenn Anderson and contains Submission of Deposition Testimony by Rochonne (Shonny) Bria; Submission of Deposition Testimony by Frances E. Contreras; Submission of Deposition Testimony by Ann E. Daley; and the first section of the Submission of Deposition Testimony by Thomas G. Seigel
[McCleary Record on Appeal]
No full textContinues the Submission of Deposition Testimony by Edwin Glenn Anderson and contains Submission of Deposition Testimony by Rochonne (Shonny) Bria; Submission of Deposition Testimony by Frances E. Contreras; Submission of Deposition Testimony by Ann E. Daley; and the first section of the Submission of Deposition Testimony by Thomas G. Seigel
- …
